Apremilast - CISMeF

Preferred Label : Apremilast;

NCIt synonyms : ( )-N-(2-((1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4-yl)acetamide;

NCIt definition : An orally bioavailable, small molecule inhibitor of phosphodiesterase 4 (PDE4), with potential anti-inflammatory activity. Upon oral administration, apremilast targets, binds to and inhibits the activity of PDE4, thereby blocking cyclic adenosine monophosphate (cAMP) degradation and increasing intracellular cAMP levels. This may decrease the production of the proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha). PDE4 is an enzyme that plays an important role in the degradation of cAMP and in cytokine production in inflammatory cells.;

UNII : UP7QBP99PN;

InChIKey : IMOZEMNVLZVGJZ-QGZVFWFLSA-N;

CAS number : 608141-41-9;

Drug name : Otezla;

Molecule name : CC-10004; CC 10004;

NCI Metathesaurus CUI : CL545011;

Détails

Origin ID

C147044;

UMLS CUI

C1678805;

Currated CISMeF NLP mapping
- Apremilast [ICD-11 Extension code]
- Apremilast [SMS substance]
- Apremilast (substance) [SNOMED CT concept]
- apremilast [MeSH concept]
- apremilast [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing apremilast (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Apremilast (substance) [SNOMED CT concept]
- Product containing apremilast (medicinal product) [SNOMED CT concept]
- apremilast [ATC Code]
- apremilast [MeSH Supplementary Concept]
- apremilast [MeSH concept]
Validated automatic mappings to BTNT
- apremilast [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients